735 autopsy reports.
Report after report, the conviction of Stephen was growing. What he was observing could not have happened by chance.
This time, he was sure. A pattern was emerging.
His hypothesis was finally confirmed. His father James had been a successful surgeon, founder of the modern scientific pathology, but his discovery could make him even more famous. The impact of what he had in front of him was far greater.
He picked up his stylograph, look at the date on the
“Huge opportunities”. “Many hurdles”. “Enormous potential”.
It's just an excerpt of the several terms you'll come across if you search for them on the web.
What am I talking about?
Exosomes. Also referred to as Prostasomes, Tolerosomes, Dexosomes, or Nanovesicles.
Markers of cancer diseases, the basis of broad diagnostic platform, and potential future therapeutics, exosomes have now surpassed 2,000 annual scientific publications.
But why are exosomes so unique?
Adeno-associated virus (AAV) is a small and single strand DNA virus. In 1960, this non-enveloped entity was accidentally discovered in adenovirus culture. It was before we understood that AAV requires the presence of another "helper" virus in order to propagate. This family was named as “Dependovirus genus”.
The genome of SARS-CoV-2 counts 29,811 nucleotides, encoding for 29 different proteins. The translation of the linear single stranded RNA conducts to the generation of the following proteome:
4 are structural proteins, S, N, M and E
16 proteins are non-structural proteins or NSP: the first 11 are encoded in ORF1a whereas the last 5 are encoded in ORF1b
9 are accessory proteins named ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10.
You are currently facing difficulties developing a robust ELISA kit for COVID-19?
Your team is still struggling to set up a state-of-the-art lateral flow test for SARS-CoV-2?
You are not sure about the appropriate mAb reference for your assay and you are afraid to lose time?
With more than 3,000,000 cases and 200,000 deaths, and after three months of worldwide outbreak, scientists keep on learning about COVID-19 every day.
How can people be positively diagnosed twice to COVID? Are serological diagnostic tests 100% reliable? Which part of the population is more likely to be infected?
Let’s review the latest updates on what we know about this challenging virus, and the on-going assay developments.
With 85 molecules under development and 3 approvals to date, it seems that bispecific antibodies may be the novel therapeutic booming class on the market.
Beyond the mechanistic advantages, bsAbs offer the possibility to combine in one single molecule the potential of two different antibodies without the related cost of two parallel development programs.
But with the victory, comes the flip side of the coin. In fact, a pretty ancient coin.